-Bloomberg
Bristol Myers Reports Positive CHMP Opinion For Anti-B-Cell Mutation Antigen CAR T Cell Therapy Abecma For Relapsed, Refractory Multiple Myeloma
Recommendation for approval based on results from pivotal KarMMa study
Abecma is the first CAR T cell therapy for adults with relapsed and refractory multiple myeloma to receive positive CHMP opinion and builds on the